These findings support the notion that, beyond their intrinsic proliferative roles, oncogenes such as MYC and KRAS critically shape the TME, ultimately facilitating tumor progression through distinct immunomodulatory pathways [30]. The gene discussed is MYC; the disease is neoplasm.